FDA approves Anthim for treatment of inhalational anthrax
The U.S. Food and Drug Administration (FDA) announced this week the approval of Anthim (oblitoxaximab) injection for the treatment of inhalational anthrax to be used in combination with antibacterial drugs. Read More »